IP Library Granted Patent US 9,410,141
Granted Patent B2
US 9,410,141 · App. 14/790,075 · Granted Aug 9, 2016

Compositions and methods of using chondroitinase ABCI mutants

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,410,141
App. No.
14/790,075
Granted
Aug 9, 2016
Kind
B2
Abstract

The present disclosure relates to protein and nucleic acid mutants of chondroitinase ABCI. Such nucleic acid mutants encode for chondroitinase ABCI mutant enzymes exhibiting altered chondroitin lyase activity or increased resistance to inactivation from stressors including UV light or heat. Methods of using such nucleic acid mutants encoding chondroitinase ABCI mutant enzymes is also provided.

Claims (17)

1. A recombinant nucleic acid sequence encoding a mutant chondroitinase ABC I enzyme, wherein the recombinant nucleic acid sequence comprises SEQ ID NO: 9.

2. The recombinant nucleic acid sequence of claim 1 , wherein the nucleic acid sequence encodes the mutant chondroitinase ABC I enzyme comprising the amino acid sequence of SEQ ID NO: 1.

3. The recombinant nucleic acid sequence of claim 1 , wherein the nucleic acid sequence is expressed by a vector.

4. The recombinant nucleic acid sequence of claim 3 , wherein the vector is selected from a plasmid, a yeast vector, a mammalian vector, a single stranded phage, a double stranded phage, a viral vector, artificial chromosome, and a combination thereof.

5. The recombinant nucleic acid sequence of claim 4 , wherein the artificial chromosome is selected from bacterial artificial chromosome (BAC), plasmid artificial chromosome (PAC), yeast artificial chromosome (YAC), and mammalian artificial chromosome (MAC).

6. The recombinant nucleic acid sequence of claim 4 , wherein the plasmid is selected from a pBR322-derived plasmid, a pEMBL-derived plasmid, a pEX-derived plasmid, a pBTac-derived plasmid, or a pUC-derived plasmid.

7. The recombinant nucleic acid sequence of claim 4 , wherein the yeast vector is selected from YEp24, YIp5, YEp51, YEp52, pYES2, and YRP17.

8. An expression vector comprising a recombinant nucleic acid sequence encoding a mutant chondroitinase ABC I enzyme, wherein the recombinant nucleic acid sequence comprises SEQ ID NO: 9.

9. The expression vector of claim 8 , wherein the recombinant nucleic acid sequence encodes the mutant chondroitinase ABC I enzyme comprising the amino acid sequence of SEQ ID NO: 1.

10. The expression vector of claim 8 , wherein the vector is selected from a plasmid, a yeast vector, a mammalian vector, a single stranded phage, a double stranded phage, a viral vector, artificial chromosome, and a combination thereof.

11. A method of making an expression vector comprising:

ligating a recombinant nucleic acid sequence to an expression vector, wherein the recombinant nucleic acid sequence comprises SEQ ID NO: 9 and encodes a mutant chondroitinase ABC I enzyme.

12. The method of claim 11 , wherein the recombinant nucleic acid sequence encodes the mutant chondroitinase ABC I enzyme comprising the amino acid sequence of SEQ ID NO: 1.

13. The method of claim 11 , wherein the expression vector is selected from a plasmid, a yeast vector, a mammalian vector, a single stranded phage, a double stranded phage, a viral vector, artificial chromosome, and a combination thereof.

14. The method of claim 13 , wherein the artificial chromosome is selected from bacterial artificial chromosome (BAC), plasmid artificial chromosome (PAC), yeast artificial chromosome (YAC), and mammalian artificial chromosome (MAC).

15. The method of claim 13 , wherein the plasmid is selected from a pBR322-derived plasmid, a pEMBL-derived plasmid, a pEX-derived plasmid, a pBTac-derived plasmid, and a pUC-derived plasmid.

16. The method of claim 13 , wherein the yeast vector is selected from YEp24, YIp5, YEp51, YEp52, pYES2, and YRP17.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded May 31, 2017
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: NEURONEX, INC.; CIVITAS THERAPEUTICS, INC.; ACORDA THERAPEUTICS, INC.
Reel/Frame 042643/0878 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 24, 2016
From: CAGGIANO, ANTHONY O.; IACI, JENNIFER; VECCHIONE, ANDREA
To: ACORDA THERAPEUTICS, INC.
Reel/Frame 039002/0334 →
SECURITY INTEREST Recorded Jun 10, 2016
From: ACORDA THERAPEUTICS, INC.; CIVITAS THERAPEUTICS, INC.; NEURONEX, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 038950/0436 →